Global private equity firm General Atlantic will invest $55 million in Kalbe Genexine Biologics (#KGBio), a joint venture of Indonesian pharmaceuticals firm PT #KalbeFarma and South Korean biotech firm #Genexine Inc.
The #investment will go towards KGBio’s ongoing clinical development and help boost its production capacity, among others.
Kalbe Farma owns a majority stake in KGBio, founded in 2016. Kalbe Farma, which operates in prescription #pharmaceuticals, consumer health, nutrition, and distribution and logistics, has a market value of $5.2 billion.
Access @reuters article via our Twitter post.
#StaySafe #StayHealthy
View on Instagram
The #investment will go towards KGBio’s ongoing clinical development and help boost its production capacity, among others.
Kalbe Farma owns a majority stake in KGBio, founded in 2016. Kalbe Farma, which operates in prescription #pharmaceuticals, consumer health, nutrition, and distribution and logistics, has a market value of $5.2 billion.
Access @reuters article via our Twitter post.
#StaySafe #StayHealthy
View on Instagram